Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis
The appreciable number of RCTs identified indicates that the treatment landscape here is rapidly evolving. The introduction of novel treatments, in the second-line setting, has not had a statistically significant impact on key efficacy outcomes, and has had little impact on safety outcomes, versus more established treatments. There remains a need for novel treatments that will have a significant benefit on efficacy and safety outcomes.
Authors
- Laura McCullagh (ORCID: https://orcid.org/0000-0001-8342-8739)
- Jacintha O’Sullivan
- Niamh Carey (ORCID: https://orcid.org/0000-0001-6174-9718)
- Patrick J. Kearns
- David J. McConnell (ORCID: https://orcid.org/0000-0003-4273-0282)
- L McCullagh
- Shikha Sharma
- P Kearns
- D McConnell
- M Lowery
- Maeve Lowery
- S. Sharma
- J O’Sullivan
- N Carey
Institutions
- Trinity College Dublin (IE)
- National Centre for Pharmacoeconomics (IE)
- St. James's Hospital (IE)
Publication Details
- Journal
- Journal of Gastrointestinal Cancer
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1007/s12029-026-01407-z
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00